Recovery
Parasym earns a Good overall score due to solid moderate evidence for taVNS effectiveness in recovery contexts like HRV enhancement (e.g., Geng et al. 2022 showed favorable HRV shifts in low baseline groups via 1-hour sessions at 1-36mA) and fatigue remission (Verbanck pilot: 20 long-COVID patients, 30min/day for 10 days reduced fatigue 48%, depression 45%, p<0.0001). Inflammation reduction (Stavrakis 2022: 61% drop in cytokines like IL-8 over 3 months) supports anti-inflammatory claims relevant
Parasym is a promising taVNS device for recovery, with moderate evidence supporting HRV, fatigue, and inflammation benefits from clinical studies. It's exceptionally safe but overpriced compared to alternatives. Suitable for those prioritizing research-backed neuromodulation despite lack of FDA approval.